Abstract
Background: Prostate cancer (PCa) is the second cause of mortality in men worldwide. The prostate-specific antigen (PSA) test is routinely adopted in diagnosis; nevertheless more reliable biomarkers are continuously under investigation by monitoring the release of molecules into the bloodstream. The serum protein profiles appear to provide cancer-specific fingerprints that help to discriminate patients (especially with low PSA level) from controls, improving the performance of existing clinical tests. Methods: Samples from healthy controls and PCa patients with low (≤. 4. ng/mL) and high PSA (>. 4. ng/mL) levels were analyzed by MALDI profiling, and by a multi fractionation approach coupled to ESI-MS for peaks identification. Results: MALDI profiling achieved to detect 10 and 14 changed peaks (p-value
Original language | English |
---|---|
Pages (from-to) | 42-49 |
Number of pages | 8 |
Journal | Clinica Chimica Acta |
Volume | 439 |
DOIs | |
Publication status | Published - Oct 12 2014 |
Keywords
- Complement C3f
- Immunodepletion
- MALDI profiling
- Prostate cancer
- Prostate-specific antigen
ASJC Scopus subject areas
- Biochemistry
- Clinical Biochemistry
- Biochemistry, medical
- Medicine(all)